Literature DB >> 23264661

Analgesic effect of switching from oral opioids to a once-a-day fentanyl citrate transdermal patch in patients with lung cancer.

Osamu Takakuwa1, Tetsuya Oguri, Ken Maeno, Midori Yokoyama, Hisatoshi Hijikata, Takehiro Uemura, Hiroaki Ozasa, Hirotsugu Ohkubo, Mikinori Miyazaki, Akio Niimi.   

Abstract

A new once-a-day fentanyl citrate transdermal patch was developed in Japan. We retrospectively investigated analgesic and adverse effects of this drug in 24 patients with lung cancer. All patients were started on this patch by switching from an oral opioid. The mean pain score before switching was 2.45 (0-5); 48 hours after switching, 15 of the 24 patients showed a decreased pain score and the mean score (2.00) was significantly lower than that before switching. Of the 16 patients who had adverse effects of oral opioids, 7 patients showed improvement in their symptoms after switching. Two patients showed adverse effects of the drug but their symptoms were mild, and no patient required dose decrease. This new transdermal patch could be a useful treatment option for cancer pain.

Entities:  

Keywords:  analgesic effect; face scale; fentanyl citrate; lung cancer; oral opioid; transdermal fentanyl

Mesh:

Substances:

Year:  2012        PMID: 23264661     DOI: 10.1177/1049909112470020

Source DB:  PubMed          Journal:  Am J Hosp Palliat Care        ISSN: 1049-9091            Impact factor:   2.500


  4 in total

1.  Long-term use of a once-a-day fentanyl citrate transdermal patch in lung cancer patients.

Authors:  Osamu Takakuwa; Tetsuya Oguri; Ken Maeno; Hiroki Murase; Takamitsu Asano; Hiroya Ichikawa; Yuko Kawaguchi; Takehiro Uemura; Hirotsugu Ohkubo; Masaya Takemura; Akio Niimi
Journal:  Oncol Lett       Date:  2015-03-09       Impact factor: 2.967

2.  A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.

Authors:  Kazuhiko Koike; Takeshi Terui; Tomokazu Nagasako; Iori Horiuchi; Takayuki Machino; Toshiro Kusakabe; Yasuo Hirayama; Hiroyoshi Mihara; Michiaki Yamakage; Junji Kato; Takuji Nishisato; Kunihiko Ishitani
Journal:  Support Care Cancer       Date:  2015-08-07       Impact factor: 3.603

3.  Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.

Authors:  Keiichiro Imanaka; Yushin Tominaga; Mila Etropolski; Hiroki Ohashi; Keiichiro Hirose; Taka Matsumura
Journal:  Clin Drug Investig       Date:  2014-07       Impact factor: 2.859

4.  Opioid switch from low dose of oral oxycodone to transdermal fentanyl matrix patch for patients with stable thoracic malignancy-related pain.

Authors:  Seigo Minami; Takashi Kijima; Takeshi Nakatani; Suguru Yamamoto; Yoshitaka Ogata; Haruhiko Hirata; Takayuki Shiroyama; Taro Koba; Kiyoshi Komuta
Journal:  BMC Palliat Care       Date:  2014-10-08       Impact factor: 3.234

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.